# Enterprise Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enterprise-therapeutics

- Industry: Biotechnology
- Headquarters: Brighton, UK
- Website: www.enterprisetherapeutics.com
- Total disclosed funding: $77M
- Latest round: Series B (Jan 26, 2024)
- Investors on record: 7

## About

Founded in 2014 and based in Brighton, UK, Enterprise Therapeutics Ltd. develops therapies for respiratory diseases such as cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD). In January 2024, Enterprise Therapeutics Ltd. raised GBP 26.41 million in series B funding led by investor Panakès Partners, with participation from investors Epidarex Capital, Forbion, IP Group, Novartis Venture Fund, and Versant Ventures. The series B round of financing values Enterprise Therapeutics Ltd. at GBP 55.54 million post-money. As of July 2024, the company is led by CEO John Ford.

Enterprise Therapeutics' primary focus is on developing drug candidates that address mucus congestion in respiratory diseases. Their lead product candidate, ETD001, is an inhaled epithelial sodium channel (ENaC) blocker designed to improve mucus clearance in the lungs. The company’s pipeline also includes other compounds targeting various mechanisms involved in mucus production and clearance for patients with severe respiratory conditions.

The company will use the January 2024 funding to conduct clinical trials for its pharmaceuticals in the second phase of development.

## Funding rounds

- Series B, Jan 26, 2024, $34M — Versant Ventures, Novartis Venture Fund, Forbion, Longview Innovation, Epidarex Capital, Panakes Partners
- Series B, Apr 6, 2018, $32M — Versant Ventures, Novartis Venture Fund, Forbion, Longview Innovation, Epidarex Capital
- Series A, Nov 4, 2016, $5M — Epidarex Capital, Touchstone Innovations
- Series A, May 5, 2015, $3.7M — Epidarex Capital, Touchstone Innovations
- Series A, Dec 1, 2014, $2.5M — Epidarex Capital

## Investors

- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Series A, Series B
- Touchstone Innovations (https://capitalatlas.ai/funds/touchstone-innovations) — Series A
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Series B
- Panakes Partners (https://capitalatlas.ai/funds/panakes-partners) — Series B